TotalMarketCap

Cabaletta Bio

CABANasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$214.475 M

$1.27 -10.91%

Close of 6 Nov 2026

As of 6 Nov 2026, Cabaletta Bio (CABA) has a market capitalization of $214.5M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$167.9M

Loss-making

Shares outstanding

215,720,392

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #91Lexeo TherapeuticsLXEO$239.6M
  2. #92Fate TherapeuticsFATE$225.9M
  3. #93Cabaletta BioCABA$214.5M
  4. #94Protalix BioTherapeuticsPLX$202.6M
  5. #95Artiva BiotherapeuticsARTV$202.4M

What if Cabaletta Bio were worth as much as…

Open the what-if tool →

Gold $28.2T

$166,544.57

Per share 131,656× higher

Bitcoin $1.53T

$9,011.44

Per share 7,124× higher

Apple $5.02T

$29,583.71

Per share 23,386× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for Cabaletta Bio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.